Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 19/20 | 0.49 |
| ▸ | PLK3 | Q9H4B4 | 9/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3265391 | 0.94 | EPHA2 (0.46) | PLK1PLK3CYP2C9CYP3A4CDK2 | |
| SCHEMBL13621648 | 0.94 | EPHA2 (0.46) | PLK1PLK3CYP2C9CYP3A4CDK2 | |
| SCHEMBL3255939 | 0.94 | EPHA2 (0.46) | PLK1PLK3CYP2C9CYP3A4CDK2 | |
| SCHEMBL3256890 | 0.92 | PLK1 (0.51) | PLK1PLK3CYP2C9CYP3A4CDK2 | |
| SCHEMBL13440276 | 0.85 | PLK1 (0.53) | PLK1PLK3CYP2C9CYP3A4CDK2 | |
| SCHEMBL3256394 | 0.85 | PLK1 (0.55) | PLK1PLK3CYP2C9CYP3A4CDK2 | |
| SCHEMBL3249008 | 0.85 | PLK1 (0.53) | PLK1PLK3CYP2C9CYP3A4CDK2 | |
| SCHEMBL3252806 | 0.85 | PLK1 (0.53) | PLK1PLK3CYP2C9CYP3A4CDK2 | |
| SCHEMBL13440203 | 0.85 | PLK1 (0.55) | PLK1PLK3CYP2C9CYP3A4CDK2 | |
| SCHEMBL14029473 | 0.84 | PLK1 (0.67) | PLK1PLK3CDK2IKBKE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075960-A1 | BENZIMIDAZOLE THIOPHENE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2010-03-25 | — | — | US | disclosed |
| US-7615643-B2 | 3-[((1R)-1-{2-Chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl}ethyl)oxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-2-thiophenecarboxamide; polo like kinase enzyme inhibitors; anticarcinogenic agents for treating cancer | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-10 | — | — | US | disclosed |
| US-7615643-B2 | 3-[((1R)-1-{2-Chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl}ethyl)oxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-2-thiophenecarboxamide; polo like kinase enzyme inhibitors; anticarcinogenic agents for treating cancer | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-10 | — | — | US | disclosed |
| US-20090124615-A9 | Benzimidazole Thiophene Compounds | KUNTZ KEVIN | 2009-05-14 | — | — | US | disclosed |
| US-20090124615-A9 | Benzimidazole Thiophene Compounds | KUNTZ KEVIN | 2009-05-14 | — | — | US | disclosed |
| US-20080300247-A1 | Benzimidazole Thiophene Compounds | KUNTZ KEVIN | 2008-12-04 | — | — | US | disclosed |
| US-20080300247-A1 | Benzimidazole Thiophene Compounds | KUNTZ KEVIN | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124615-A9 | Benzimidazole Thiophene Compounds | ABCB1, CYP3A5, ABCG2 | PLK1 458/4885PLK3 1235/4885CYP2C9 7/4885 |
| US-20080300247-A1 | Benzimidazole Thiophene Compounds | ABCB1, CYP3A5, ABCG2 | PLK1 458/4885PLK3 1235/4885CYP2C9 7/4885 |
| US-20100075960-A1 | BENZIMIDAZOLE THIOPHENE COMPOUNDS | ABCB1, CYP3A5, CYP3A4 | PLK1 450/4885PLK3 1025/4885CYP2C9 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.